Jazz Pharmaceuticals plcJAZZEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 10.11% | 6.4M | ▼ -0.15pp | 2024-02-13 |
| BlackRock, Inc. | 9.50% | 5.9M | flat | 2024-11-12 |
Insider Transactions
Net 90d: −$15.30M · buys $0 / sells $15.30MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | COZADD BRUCE C | Director | Sell (open market) | 3.7K | $190.22 | $700.8K |
| 2026-04-01 | COZADD BRUCE C | Director | Sell (open market) | 2.3K | $190.94 | $437.6K |
| 2026-04-01 | COZADD BRUCE C | Director | Sell (open market) | 24 | $191.74 | $4.6K |
| 2026-03-09 | Patricia Carr | SVP, Chief Accounting Officer | Sell (open market) | 1.3K | $182.94 | $235.4K |
| 2026-03-03 | COZADD BRUCE C | Director | Sell (open market) | 3.2K | $186.09 | $587.8K |
| 2026-03-03 | COZADD BRUCE C | Director | Sell (open market) | 2.6K | $186.73 | $487.0K |
| 2026-03-03 | COZADD BRUCE C | Director | Sell (open market) | 233 | $187.84 | $43.8K |
| 2026-02-27 | RIEDEL NORBERT G | Director | Option exercise | 3.4K | $138.08 | $471.5K |
| 2026-02-27 | RIEDEL NORBERT G | Director | Sell (open market) | 3.4K | $192.00 | $655.7K |
| 2026-02-27 | Patricia Carr | SVP, Chief Accounting Officer | Sell (open market) | 1.1K | $190.91 | $213.2K |
1–10 of 35
Page 1 / 4